Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

SML0327

Sigma-Aldrich

AM630

≥90% (HPLC)

Sinonimo/i:

6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, AM 630, Iodopravadoline

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C23H25IN2O3
Numero CAS:
164178-33-0
Peso molecolare:
504.36
Numero MDL:
MFCD01861183
Codice UNSPSC:
12352200
ID PubChem:
329825332
NACRES:
NA.77

Saggio

≥90% (HPLC)

Forma fisica

powder

Condizioni di stoccaggio

desiccated

Colore

white to beige

Solubilità

DMSO: >5 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

COc1ccc(cc1)C(=O)c2c(C)n(CCN3CCOCC3)c4cc(I)ccc24

InChI

1S/C23H25IN2O3/c1-16-22(23(27)17-3-6-19(28-2)7-4-17)20-8-5-18(24)15-21(20)26(16)10-9-25-11-13-29-14-12-25/h3-8,15H,9-14H2,1-2H3
JHOTYHDSLIUKCJ-UHFFFAOYSA-N

Applicazioni

AM630 has been used:
  • as a cannabinoid 2(CB2) inhibitor to study the analgesic effect exerted by polysaccharopeptide from Trametes versicolor (TPSP).
  • as a CB2 antagonist along with β-caryophyllene (BCP) to study its effects on re-epithilialization of fibroblast cells.
  • as a CB2 antagonist to study its interaction with 17-β-estradiol in primary human osteoblasts.

Azioni biochim/fisiol

AM630 is a selective CB2 cannabinoid antagonist/inverse agonist (Ki = 31.2 nM) with > 150-fold selectivity over CB1 receptors.
AM630 is an aminoalkylindole and acts as a competitive antagonist of CP 55,940 and WIN 55,212-2. It also behaves as a competitive antagonist of anandamide and (R)-(+)-arachidonyl-1′-hydroxy-2′-propylamide (AM356).

Caratteristiche e vantaggi

This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pittogrammi

Environment
GHS09

Avvertenze

Warning

Indicazioni di pericolo

H410

Consigli di prudenza

P273 - P391 - P501

Classi di pericolo

Aquatic Acute 1 - Aquatic Chronic 1

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Marko Hojnik et al.
Biomedical reports, 3(4), 554-558 (2015-07-15)
The bone remodeling process is influenced by various factors, including estrogens and transmitters of the endocannabinoid system. In osteoblasts, cannabinoid receptors 2 (CB-2) are expressed at a much higher level compared to CB-1 receptors. Previous studies have shown that estrogens
K A Jenkin et al.
British journal of pharmacology, 173(7), 1128-1142 (2014-12-30)
In diabetic nephropathy agonism of CB2 receptors reduces albuminuria and podocyte loss; however, the role of CB2 receptors in obesity-related nephropathy is unknown. The aim of this study was to determine the role of CB2 receptors in a model of
Massimo Nabissi et al.
Oncotarget, 7(47), 77543-77557 (2016-10-22)
Several studies showed a potential anti-tumor role for cannabinoids, by modulating cell signaling pathways involved in cancer cell proliferation, chemo-resistance and migration. Cannabidiol (CBD) was previously noted in multiple myeloma (MM), both alone and in synergy with the proteasome inhibitor
Sachiko Koyama et al.
PloS one, 14(12), e0216104-e0216104 (2019-12-17)
Beta-caryophyllene is an odoriferous bicyclic sesquiterpene found in various herbs and spices. Recently, it was found that beta-caryophyllene is a ligand of the cannabinoid receptor 2 (CB2). Activation of CB2 will decrease pain, a major signal for inflammatory responses. We
Elahe Mohammadi Vosough et al.
Life sciences, 232, 116670-116670 (2019-07-23)
Migraine is a neurological debilitating disorder. Previous studies have shown that cannabinoid receptor agonists have analgesic effects in various models of pain. In this study, therefore, we investigated anti-nociceptive effects of WIN 55,212-2, and the role of either CB1 or
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.